EP0881219A4 - Derives de la dioxothiazolidylbenzamide substitues en n et leur procede d'obtention - Google Patents

Derives de la dioxothiazolidylbenzamide substitues en n et leur procede d'obtention

Info

Publication number
EP0881219A4
EP0881219A4 EP96942555A EP96942555A EP0881219A4 EP 0881219 A4 EP0881219 A4 EP 0881219A4 EP 96942555 A EP96942555 A EP 96942555A EP 96942555 A EP96942555 A EP 96942555A EP 0881219 A4 EP0881219 A4 EP 0881219A4
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
denotes
groups
group
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP96942555A
Other languages
German (de)
English (en)
Other versions
EP0881219B1 (fr
EP0881219A1 (fr
Inventor
Toshio Maeda
Masahiro Nomura
Katsuya Awano
Susumu Kinoshita
Hiroya Satoh
Koji Murakami
Masaki Tsunoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of EP0881219A1 publication Critical patent/EP0881219A1/fr
Publication of EP0881219A4 publication Critical patent/EP0881219A4/fr
Application granted granted Critical
Publication of EP0881219B1 publication Critical patent/EP0881219B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP96942555A 1995-12-18 1996-12-16 Derives de la dioxothiazolidylbenzamide substitues en n et leur procede d'obtention Expired - Lifetime EP0881219B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP34834195 1995-12-18
JP34834195A JP3906935B2 (ja) 1995-12-18 1995-12-18 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
JP348341/95 1995-12-18
PCT/JP1996/003664 WO1997022600A1 (fr) 1995-12-18 1996-12-16 Derives de la dioxothiazolidylbenzamide substitues en n et leur procede d'obtention

Publications (3)

Publication Number Publication Date
EP0881219A1 EP0881219A1 (fr) 1998-12-02
EP0881219A4 true EP0881219A4 (fr) 2000-01-26
EP0881219B1 EP0881219B1 (fr) 2004-04-07

Family

ID=18396383

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96942555A Expired - Lifetime EP0881219B1 (fr) 1995-12-18 1996-12-16 Derives de la dioxothiazolidylbenzamide substitues en n et leur procede d'obtention

Country Status (12)

Country Link
US (1) US5948803A (fr)
EP (1) EP0881219B1 (fr)
JP (1) JP3906935B2 (fr)
KR (1) KR100492655B1 (fr)
CN (1) CN1065863C (fr)
AT (1) ATE263759T1 (fr)
AU (1) AU705538B2 (fr)
CA (1) CA2239245C (fr)
DE (1) DE69632152T2 (fr)
HU (1) HUP0000449A3 (fr)
TW (1) TW339333B (fr)
WO (1) WO1997022600A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147101A (en) * 1995-06-02 2000-11-14 Kyorin Pharmaceutical Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
WO1998020871A1 (fr) * 1996-11-08 1998-05-22 Nippon Chemiphar Co., Ltd. Agent diminuant la graisse viscerale
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
AU740733B2 (en) * 1997-12-19 2001-11-15 Merck & Co., Inc. Arylthiazolidinedione derivatives
CA2377246A1 (fr) 1999-06-18 2000-12-28 Ranjit C. Desai Derives d'arylthiazolidinedione et d'aryloxazolidinedione
CA2376919C (fr) 1999-06-18 2008-11-04 Merck & Co., Inc. Derives d'arylthiazolidinedione et d'aryloxazolidinedione
WO2001014349A1 (fr) * 1999-08-23 2001-03-01 Kyorin Pharmaceutical Co., Ltd. Derives de benzylthiazolidine-2,4-dione substitues
AU781076B2 (en) 1999-08-23 2005-05-05 Kyorin Pharmaceutical Co. Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
EP1207156B1 (fr) * 1999-08-23 2005-05-18 Kyorin Pharmaceutical Co., Ltd. Derives de benzylthiazolidine-2,4-dione substitues
DE60025621T2 (de) * 1999-09-17 2006-11-23 Kyorin Pharmaceutical Co., Ltd. O-anisamid-derivate
WO2002046161A1 (fr) * 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives de l'acide carboxylique substitues
KR100965201B1 (ko) * 2001-06-12 2010-06-24 웰스테트 테라퓨틱스 코포레이션 대사 질환의 치료용 화합물
WO2003042190A1 (fr) 2001-11-12 2003-05-22 Pfizer Products Inc. Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) * 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
ES2281801T3 (es) * 2003-05-12 2007-10-01 Pfizer Products Inc. Inhibidores benzamida del receptor p2x7.
EP1837330B1 (fr) * 2003-05-12 2012-10-24 Pfizer Products Inc. Inhibiteurs benzamidiques du recepteur P2X7
JP2008504362A (ja) * 2004-06-29 2008-02-14 ファイザー・プロダクツ・インク Ｐ２ｘ７阻害活性をもつ５−［４−（２−ヒドロキシ−エチル）−３，５−ジオキソ−４，５−ジヒドロ−３ｈ−［１，２，４］トリアジン−２−イル］−ベンズアミド誘導体を、トリアジンの４−位において置換されていない誘導体とオキシランをルイス酸の存在下で反応させることにより製造する方法
CA2572119A1 (fr) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Therapies combinatoires dans lesquelles sont utilises des inhibiteurs de benzamide du recepteur p2x<sb>7</sb>
BRPI0512781A (pt) * 2004-06-29 2008-04-08 Pfizer Prod Inc método para preparação de derivados de 5-{4-(2-hidroxi-propil)-3,5-dioxo-4,5-diidro-3h-[1,2,4]tria zin-2-il}-benzamida através da desproteção dos precursores de protetores de hidroxila
US20100227901A1 (en) * 2006-02-28 2010-09-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP3323820B1 (fr) 2011-02-28 2023-05-10 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
DK3628670T3 (da) 2012-04-13 2022-12-05 Epizyme Inc Saltform til ezh2-hæmning
CN105102432B (zh) 2012-10-15 2019-01-04 Epizyme股份有限公司 经取代的苯化合物
EP3057962B1 (fr) 2013-10-16 2023-10-18 Epizyme, Inc. Forme saline d'hydrochlorure pour inhibition d'ezh2
CN108929263B (zh) * 2017-05-26 2022-07-22 中国医学科学院药物研究所 芳酰胺类Kv2.1抑制剂及其制备方法、药物组合物和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0033617A2 (fr) * 1980-01-24 1981-08-12 Takeda Chemical Industries, Ltd. Dérivés de la thiazolidine, leur préparation et médicaments les contenant
EP0332331A2 (fr) * 1988-03-08 1989-09-13 Pfizer Inc. Thiazolidine diones comme agents hypoglycémiques
EP0526658A1 (fr) * 1991-02-25 1993-02-10 Kyorin Pharmaceutical Co., Ltd. Derive de thiazolidine-2, 4, sel dudit derive et leur production

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5728073A (en) * 1980-07-29 1982-02-15 Takeda Chem Ind Ltd Inhibitor for aldose reducing enzyme
WO1989008652A1 (fr) * 1988-03-08 1989-09-21 Pfizer Inc. Derives de thiazolidinedione comme agents hypoglycemiques
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
JPH04270273A (ja) * 1991-02-25 1992-09-25 Kyorin Pharmaceut Co Ltd チアゾリジン−２，４−ジオン誘導体とその塩及びその製造法
FR2696743B1 (fr) * 1992-10-12 1994-12-23 Adir Nouveaux composés de thiazolidine dione, leur procédé de préparation et les compositions pharmaceutiques les contenant.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0033617A2 (fr) * 1980-01-24 1981-08-12 Takeda Chemical Industries, Ltd. Dérivés de la thiazolidine, leur préparation et médicaments les contenant
EP0332331A2 (fr) * 1988-03-08 1989-09-13 Pfizer Inc. Thiazolidine diones comme agents hypoglycémiques
EP0526658A1 (fr) * 1991-02-25 1993-02-10 Kyorin Pharmaceutical Co., Ltd. Derive de thiazolidine-2, 4, sel dudit derive et leur production
JPH0592960A (ja) * 1991-02-25 1993-04-16 Kyorin Pharmaceut Co Ltd チアゾリジン−２，４−ジオン誘導体とその塩及び製造法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 110, no. 17, 24 April 1989, Columbus, Ohio, US; abstract no. 150323, XP002123273 *
G. KLOPMAN ET AL., MOL. PHARMACOL., vol. 34, no. 6, 1988, pages 852 - 862 *
SOHDA T ET AL: "STUDIES ON ANTIDIABETIC AGENTS. III. 5-ARYLTHIAZOLIDINE-2,4-DIONES AS POTENT ALDOSE REDUCTASE INHIBITORS", CHEMICAL AND PHARMACEUTICAL BULLETIN,JP,PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, vol. 30, no. 10, 1982, pages 3601-3616, XP002024094, ISSN: 0009-2363 *

Also Published As

Publication number Publication date
CA2239245C (fr) 2004-03-30
KR20000064428A (ko) 2000-11-06
JPH09169746A (ja) 1997-06-30
HUP0000449A2 (hu) 2001-02-28
AU2011697A (en) 1997-07-14
DE69632152T2 (de) 2005-02-24
EP0881219B1 (fr) 2004-04-07
CA2239245A1 (fr) 1997-06-26
TW339333B (en) 1998-09-01
CN1205695A (zh) 1999-01-20
AU705538B2 (en) 1999-05-27
KR100492655B1 (ko) 2005-09-07
WO1997022600A1 (fr) 1997-06-26
US5948803A (en) 1999-09-07
EP0881219A1 (fr) 1998-12-02
JP3906935B2 (ja) 2007-04-18
CN1065863C (zh) 2001-05-16
HUP0000449A3 (en) 2001-04-28
DE69632152D1 (de) 2004-05-13
ATE263759T1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
AU2011697A (en) N-substituted dioxothiazolidylbenzamide derivatives and the process for preparing the same
AU698896B2 (en) N-benzyldioxothiazolidylbenzamide derivatives and processes for preparing the same
DE68906552D1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung.
DK0826688T3 (da) Pentacykliske forbindelser
EP0733621A4 (fr) Nouveau derive de l&#39;imidazole et sa methode d&#39;obtention
HU913062D0 (en) Method for producing benzol, pyridyl and pyridine derivatives and pharmaceutical preparatives containing such compounds
ATE138571T1 (de) Verwendung von dioxabicyclo (3.3.0&gt;octane derivaten zur herstellung eines arzneimittels zur hemmung des cholesterinmetabolismus.
DE69529619D1 (en) Pyrimidinylpyrazolderivate
ES2166021T3 (es) Procedimiento para la preparacion de 4-aril-3-hidroximetilpiperidinas.
HU9202285D0 (en) Method for producing spicamycine derivatives
ES2169220T3 (es) Derivados de vitamina d3 con sustituyentes en la posicion 2.
ES2064557T3 (es) Derivados de 1-fenilalquil-3-fenilurea.
IE901314L (en) 2- substituted-n,n&#39;-di(trimethoxybenzoyl)piperazines
EP0376633A3 (fr) Dérivés de benzoxazépine
EP0948964A4 (fr) Nouveaux derives de pyrrolidine n-substitues et procede de preparation de ces derives
AU7332996A (en) Therapeutics for thrombocytopenia
ATE155785T1 (de) Mitomycinderivate
DE3879058D1 (de) 4-piperidincarboxamid-derivate.
EP0441116A3 (en) Optically active chroman derivatives and intermediates thereof, and process for manufacturing same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980617

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991210

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010129

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040407

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040407

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040407

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040407

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040407

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040407

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040407

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69632152

Country of ref document: DE

Date of ref document: 20040513

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040707

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040707

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040707

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041216

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041231

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050110

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040907

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20071212

Year of fee payment: 12

Ref country code: FR

Payment date: 20071210

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20071213

Year of fee payment: 12

Ref country code: IT

Payment date: 20071228

Year of fee payment: 12

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20081216

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20090831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081216